MAXCYTE INC. - COMMON STOCK
3.8500
21-February-25 16:45:00
15 minutes delayed
Stocks
-0.1100
-2.78%
Today's range
3.8100 - 4.0800
ISIN
N/A
Source
NASDAQ
-
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
06 Jul 2023 08:05:05 By Nasdaq GlobeNewswire
-
MaxCyte to Participate in Upcoming Investor Conferences
01 Jun 2023 16:05:00 By Nasdaq GlobeNewswire
-
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
10 May 2023 16:05:01 By Nasdaq GlobeNewswire
-
04 May 2023 08:05:53 By Nasdaq GlobeNewswire
-
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
12 Apr 2023 16:05:30 By Nasdaq GlobeNewswire
-
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
27 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 16:05:23 By Nasdaq GlobeNewswire
-
08 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
01 Feb 2023 16:05:53 By Nasdaq GlobeNewswire
-
03 Jan 2023 16:05:00 By Nasdaq GlobeNewswire
-
05 Dec 2022 02:00:00 By Nasdaq GlobeNewswire
-
MaxCyte Reports Third Quarter 2022 Financial Results
09 Nov 2022 16:05:03 By Nasdaq GlobeNewswire
-
MaxCyte to Participate in Upcoming Investor Conferences
02 Nov 2022 08:05:00 By Nasdaq GlobeNewswire
-
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
12 Oct 2022 08:00:01 By Nasdaq GlobeNewswire
-
28 Sep 2022 08:05:00 By Nasdaq GlobeNewswire
-
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
21 Sep 2022 08:05:00 By Nasdaq GlobeNewswire
-
MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
07 Sep 2022 16:05:00 By Nasdaq GlobeNewswire
-
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
10 Aug 2022 16:05:01 By Nasdaq GlobeNewswire
-
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
15 Jul 2022 08:00:00 By Nasdaq GlobeNewswire